Summary
PROJECT SUMMARY ABSTRACT High-grade serous ovarian carcinoma (HGSOC) is the most prevalent histosubtype of epithelial ovarian cancer. Therapy for HGSOC relies on DNA damaging agents, with a high percentage of cancers having de novo or acquired chemoresistance due in part to homologous recombination (HR) proficiency. Our preliminary data has uncovered a potential metabolic mechanism contributing to HR proficiency that could be used for novel targeted therapies for HGSOC. This proposal tests the overarching hypothesis that acetylcarnitine increases site specific histone acetylation post-translat
